Xencor

- NASDAQ:XNCR
Last Updated 2021-07-29
  • Xencor develops superior monoclonal antibody therapeutics to treat autoimmune disorders, asthma, allergic diseases and cancer.
  • Locations

    • Monrovia CA
  • Total Funding (USD)

    8.0 million
  • Industries

    Software, Mobile Apps, Real Estate, Cyber Security, Internet
  • Security

    Type: ORD
    CUSIP: 98401F105
    ISIN: US98401F1057
Filter date
All
Bookmark Created by Last updated
There were no results found.
Filter date
All
Article Author Published
There were no results found.

Request a demo to view additional historical data, and much more.